The short explanation
For stage 1 seminoma, both surveillance and a short course of chemotherapy are widely accepted options, and overall survival is very high with either. With surveillance, you have regular check-ups, blood tests and scans, and treatment is given only if the cancer comes back, which happens in a minority of men. With adjuvant chemotherapy, the chance of it coming back falls further, but you accept the side effects of treatment that many men will never have needed. The choice often depends on your risk factors in the pathology report, how reliably you can attend frequent follow-up, how you feel about uncertainty, and your plans for children.
What depends on your situation
The parts of this that change from person to person. Uncertainty is stated, not hidden.
- Surveillance means visits and scans for several years. If travel, cost or work makes regular follow-up hard, tell your oncologist, as that is an important factor.
- Ask what the report says about the tumour's size and whether it invaded blood vessels or nearby tissue, as these affect the risk of return.
What this answer cannot determine
The boundary of online education. These need a clinician who can see you.
- This cannot recommend an option for you. Your oncologist has your full report.
Questions for your clinician
Take these with you. You can add any of them to an appointment card.
- What is my personal risk of the cancer coming back?
- What does surveillance involve and how often?
- What are the side effects of the chemotherapy?
- Does either option affect my fertility?
When to seek help
Clinician-approved guidance for this topic. When in doubt, being seen is never the wrong choice.
Emergency — call 112 now
- Call 112 or go to an emergency department if you develop fever or difficulty breathing during chemotherapy.
Book an appointment soon
- Contact your team within days if you notice a new lump, back pain, or swelling in the neck.
Raise it at a routine appointment
- Keep every scheduled follow-up visit and test.
Sources
The evidence this explanation is built on.
- Testicular cancer National Cancer Institute (NIH)
- Testicular cancer NHS
- Testicular cancer MedlinePlus (US National Library of Medicine)
Who wrote and reviewed this
Every AskHim answer names its author. A clinically reviewed answer also names the clinician who signed it off — if no clinician is named below, it has not been clinically reviewed.
- Author
- AskHim Editorial (AI-assisted)
- Clinical reviewer
- Nobody yet No clinician has signed this answer off. That is what the “Editorially reviewed” badge means, and why it does not say “Clinically reviewed”. It was written and checked by AskHim’s editorial team against the sources listed above, and it is queued for a clinician who works in this area.
- Review status
- Editorially reviewed
- Last reviewed
- Last reviewed 11 November 2026
- Version
- 1
Correction history
Substantive changes are listed, not quietly edited away.
No corrections have been made since this answer was first published.
Did this answer your question?
Whatever you choose is filed against this version of the answer, never against you, and it is never shown as a count.
“Explain more simply” asks which part was hard to follow, so the author knows what to rewrite. “My question is different” tells the editorial team this answer missed your point, then lets you ask your own question privately. Nothing about you is sent with either.
Saving, following up and reporting are all private. Nothing you do on this page is visible to other readers or to the doctor who wrote it, unless you ask a question.